BR112022016991A2 - Métodos para tratar um indivíduo humano que sofre de síndrome do desconforto respiratório agudo induzida por coronavírus ou pneumonia, para tratar, prevenir ou reduzir a gravidade ou coagulação ou trombose em um indivíduo humano infectado com vírus coronavírus da síndrome respiratória aguda grave 2 e para tratar, melhorar, prevenir ou reduzir o risco de desenvolver uma ou mais sequelas de longo prazo relacionadas ao coronavírus - Google Patents

Métodos para tratar um indivíduo humano que sofre de síndrome do desconforto respiratório agudo induzida por coronavírus ou pneumonia, para tratar, prevenir ou reduzir a gravidade ou coagulação ou trombose em um indivíduo humano infectado com vírus coronavírus da síndrome respiratória aguda grave 2 e para tratar, melhorar, prevenir ou reduzir o risco de desenvolver uma ou mais sequelas de longo prazo relacionadas ao coronavírus

Info

Publication number
BR112022016991A2
BR112022016991A2 BR112022016991A BR112022016991A BR112022016991A2 BR 112022016991 A2 BR112022016991 A2 BR 112022016991A2 BR 112022016991 A BR112022016991 A BR 112022016991A BR 112022016991 A BR112022016991 A BR 112022016991A BR 112022016991 A2 BR112022016991 A2 BR 112022016991A2
Authority
BR
Brazil
Prior art keywords
coronavirus
acute respiratory
human subject
masp
pneumonia
Prior art date
Application number
BR112022016991A
Other languages
English (en)
Inventor
A Demopulos Gregory
J Quinton Tineka
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of BR112022016991A2 publication Critical patent/BR112022016991A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrostatic Separation (AREA)

Abstract

MÉTODOS PARA TRATAR UM INDIVÍDUO HUMANO QUE SOFRE DE SÍNDROME DO DESCONFORTO RESPIRATÓRIO AGUDO INDUZIDA POR CORONAVÍRUS OU PNEUMONIA, PARA TRATAR, PREVENIR OU REDUZIR A GRAVIDADE OU COAGULAÇÃO OU TROMBOSE EM UM INDIVÍDUO HUMANO INFECTADO COM VÍRUS CORONAVÍRUS DA SÍNDROME RESPIRATÓRIA AGUDA GRAVE 2 E PARA TRATAR, MELHORAR, PREVENIR OU REDUZIR O RISCO DE DESENVOLVER UMA OU MAIS SEQUELAS DE LONGO PRAZO RELACIONADAS AO CORONAVÍRUS. Em um aspecto, a invenção provê métodos para tratar, inibir, aliviar ou prevenir a síndrome do desconforto respiratório agudo, pneumonia ou alguma outra manifestação pulmonar ou outra de infecção por coronavírus, como trombose, em um indivíduo mamífero infectado com coronavírus, como SARS-CoV-2. Os métodos compreendem a etapa de administrar a um indivíduo infectado com coronavírus uma quantidade de um agente inibidor de MASP-2 eficaz para inibir a ativação do complemento dependente de MASP-2. Em uma modalidade, o agente inibidor de MASP-2 é um anticorpo monoclonal MASP-2 ou fragmento do mesmo que especificamente se liga a uma porção de SEQ ID NO:6. Em uma modalidade, o agente inibidor de MASP-2 é um composto inibidor de MASP-2 de molécula pequena. Em uma modalidade, o indivíduo é um indivíduo humano que sofre de síndrome do desconforto respiratório agudo (SDRA) induzida por COVID-19 e requer oxigênio suplementar antes do tratamento e o agente inibidor de MASP-2 é administrado em uma quantidade suficiente para descontinuar a necessidade de oxigênio suplementar.
BR112022016991A 2020-03-06 2021-03-05 Métodos para tratar um indivíduo humano que sofre de síndrome do desconforto respiratório agudo induzida por coronavírus ou pneumonia, para tratar, prevenir ou reduzir a gravidade ou coagulação ou trombose em um indivíduo humano infectado com vírus coronavírus da síndrome respiratória aguda grave 2 e para tratar, melhorar, prevenir ou reduzir o risco de desenvolver uma ou mais sequelas de longo prazo relacionadas ao coronavírus BR112022016991A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062986566P 2020-03-06 2020-03-06
US202063008540P 2020-04-10 2020-04-10
US202063015299P 2020-04-24 2020-04-24
US202063054298P 2020-07-21 2020-07-21
US202063062843P 2020-08-07 2020-08-07
US202063104229P 2020-10-22 2020-10-22
US202063105637P 2020-10-26 2020-10-26
US202163140591P 2021-01-22 2021-01-22
PCT/US2021/021217 WO2021178902A1 (en) 2020-03-06 2021-03-05 Methods of inhibiting masp-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome

Publications (1)

Publication Number Publication Date
BR112022016991A2 true BR112022016991A2 (pt) 2022-12-06

Family

ID=77614472

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016991A BR112022016991A2 (pt) 2020-03-06 2021-03-05 Métodos para tratar um indivíduo humano que sofre de síndrome do desconforto respiratório agudo induzida por coronavírus ou pneumonia, para tratar, prevenir ou reduzir a gravidade ou coagulação ou trombose em um indivíduo humano infectado com vírus coronavírus da síndrome respiratória aguda grave 2 e para tratar, melhorar, prevenir ou reduzir o risco de desenvolver uma ou mais sequelas de longo prazo relacionadas ao coronavírus

Country Status (12)

Country Link
US (1) US20210292436A1 (pt)
EP (1) EP4114522A4 (pt)
JP (1) JP7530437B2 (pt)
KR (1) KR20220152554A (pt)
CN (3) CN118320092A (pt)
AU (1) AU2021231892A1 (pt)
BR (1) BR112022016991A2 (pt)
CA (1) CA3169034A1 (pt)
IL (1) IL296240A (pt)
MX (1) MX2022010449A (pt)
TW (2) TW202319069A (pt)
WO (1) WO2021178902A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112237630A (zh) * 2020-02-21 2021-01-19 中国人民解放军军事科学院军事医学研究院 针对masp-2、冠状病毒n蛋白或其结合的物质在制备冠状病毒所致疾病药物中的应用
CN112023045A (zh) * 2020-03-31 2020-12-04 中国人民解放军军事科学院军事医学研究院 抑制masp-2及其下游补体活化效应的物质在制备冠状病毒所致疾病药物中的应用
IL313331A (en) 2021-12-10 2024-08-01 Omeros Corp Therapeutic antibodies that bind to the SERINE PROTEASE domain of MASP-2 and uses thereof
WO2023174039A1 (en) * 2022-03-18 2023-09-21 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Masp-2-targetting antibodies and uses thereof
WO2024081269A1 (en) * 2022-10-10 2024-04-18 Dixit Rohan Therapeutic combinations and methods to treat long covid
US20240228499A1 (en) 2022-11-30 2024-07-11 Omeros Corporation Masp-2 inhibitors and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3102252A1 (en) * 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
CN107011443B (zh) * 2011-05-04 2021-04-30 奥默罗斯公司 用于抑制masp-2依赖的补体活化的组合物
EP4119577A3 (en) * 2012-06-18 2023-11-08 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
WO2014076567A1 (en) * 2012-11-13 2014-05-22 Biogenius Llc Compositions and methods for treating inflammatory diseases of infectious and non-infectious origin
WO2019231935A1 (en) * 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
US20200140570A1 (en) * 2018-06-22 2020-05-07 Omeros Corporation Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various Thrombotic Diseases and Disorders
CN112237630A (zh) * 2020-02-21 2021-01-19 中国人民解放军军事科学院军事医学研究院 针对masp-2、冠状病毒n蛋白或其结合的物质在制备冠状病毒所致疾病药物中的应用
CN112023045A (zh) * 2020-03-31 2020-12-04 中国人民解放军军事科学院军事医学研究院 抑制masp-2及其下游补体活化效应的物质在制备冠状病毒所致疾病药物中的应用

Also Published As

Publication number Publication date
JP2023516727A (ja) 2023-04-20
EP4114522A4 (en) 2024-05-01
TW202319069A (zh) 2023-05-16
TWI834025B (zh) 2024-03-01
IL296240A (en) 2022-11-01
KR20220152554A (ko) 2022-11-16
WO2021178902A1 (en) 2021-09-10
JP7530437B2 (ja) 2024-08-07
MX2022010449A (es) 2022-11-16
US20210292436A1 (en) 2021-09-23
CA3169034A1 (en) 2021-09-10
CN118320092A (zh) 2024-07-12
AU2021231892A1 (en) 2022-10-20
CN118662635A (zh) 2024-09-20
EP4114522A1 (en) 2023-01-11
TW202146047A (zh) 2021-12-16
CN115335120A (zh) 2022-11-11

Similar Documents

Publication Publication Date Title
BR112022016991A2 (pt) Métodos para tratar um indivíduo humano que sofre de síndrome do desconforto respiratório agudo induzida por coronavírus ou pneumonia, para tratar, prevenir ou reduzir a gravidade ou coagulação ou trombose em um indivíduo humano infectado com vírus coronavírus da síndrome respiratória aguda grave 2 e para tratar, melhorar, prevenir ou reduzir o risco de desenvolver uma ou mais sequelas de longo prazo relacionadas ao coronavírus
BR112018069732A2 (pt) métodos para prevenir, tratar, reverter e/ou retardar angiogênese em um sujeito mamífero, para tratar um sujeito que sofre de uma doença ou condição angiogênica ocular e para inibir angiogênese do tumor
Miesbach Pathological role of angiotensin II in severe COVID-19
Welker et al. 2021 Acute respiratory distress syndrome update, with coronavirus disease 2019 focus
Rab et al. Cigarette smoke and CFTR: implications in the pathogenesis of COPD
BR112021024310A2 (pt) Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
BR112018075682A2 (pt) inibidores de papd5 e papd7 para tratamento de infecção pela hepatite b
Ravnskov et al. Statins do not protect against cancer: quite the opposite
BR112022024662A2 (pt) Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
Tamura et al. Excretions/secretions from medicinal larvae (Lucilia sericata) inhibit complement activation by two mechanisms
BR112019007843A2 (pt) métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9)
BR112021021908A2 (pt) Composições úteis no tratamento da leucodistrofia metacromática
Bauersachs et al. CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency
EA202190106A1 (ru) Композиции и способы ингибирования masp-2 для лечения различных тромботических заболеваний и расстройств
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
BR112022022599A2 (pt) Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
Ma et al. Low dose tunicamycin enhances atherosclerotic plaque stability by inducing autophagy
Piantoni et al. Response to:‘Correspondence on ‘Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome’’by Kawada
BR112022019685A2 (pt) Composições de ácido siálico para uso na inibição ou no tratamento de infecções por coronavírus
Pang et al. Niacin promotes revascularization and recovery of limb function in diet‐induced obese mice with peripheral ischemia
BR112023002085A2 (pt) Métodos para tratar hipercolesterolemia refratária envolvendo inibidor de angptl3
MX2023011974A (es) Aptameros para usarse en el tratamiento contra infecciones por coronaviridae.
Smithies et al. Role of the tissue factor pathway in the pathogenesis and management of multiple organ failure
BR112023017582A2 (pt) Composições para o tratamento de doenças ou condições associadas ao ebv